← Back to Search

Statins

XueZhiKang (XZK) for Lipid Disorder

Phase 1
Waitlist Available
Research Sponsored by Luye Pharma Group Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 days
Awards & highlights

Summary

The objective of this study is to compare laboratory tests profiles of a botanic drug XueZhiKang (XZK) 300 mg capsules versus a marketed drug Lovastatin 20 mg tablets in healthy male volunteers between 18 and 50 years of age.

Eligible Conditions
  • Lipid Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
AUC for the Pharmacokinetics (PK) of XZK

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: XueZhiKang (XZK)Experimental Treatment1 Intervention
XueZhiKang (XZK) 1200 mg
Group II: LovastatinActive Control1 Intervention
Lovastatin 20 mg
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
XueZhiKang
2015
Completed Phase 4
~80

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Luye Pharma Group Ltd.Lead Sponsor
64 Previous Clinical Trials
9,743 Total Patients Enrolled
Simon LI, M.D.Study ChairLuye Pharma
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top